Carl Hull Becomes Chief Executive Officer of Gen-Probe

- Hank Nordhoff Now Non-Executive Chairman of the Board -

SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq:
GPRO) announced today that Carl W. Hull has formally succeeded the Company's
long-time leader, Henry L. Nordhoff, as chief executive officer (CEO). Mr.
Hull, formerly Gen-Probe's president and chief operating officer, also has
joined the Company's board of directors.

As first announced on March 23, Mr. Nordhoff retired as CEO yesterday. Mr.
Nordhoff, who had served as Gen-Probe's CEO since 1994, is now non-executive
chairman following his re-election to the board at the Company's annual
meeting of stockholders last week.

"Hank Nordhoff has built a successful and dynamic company in his 15 years at
the helm of Gen-Probe, and helped safeguard the health of literally millions
of people worldwide through our blood screening and infectious disease testing
products," Mr. Hull said. "I am honored by the opportunity to succeed him,
and look forward to his continued guidance as chairman of our board."

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and
marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that
are used primarily to diagnose human diseases and screen donated human blood.
Gen-Probe has more than 25 years of NAT expertise, and received the 2004
National Medal of Technology, America's highest honor for technological
innovation, for developing NAT assays for blood screening. Gen-Probe is
headquartered in San Diego and employs approximately 1,200 people. For more
information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release relating to expectations, beliefs, plans,
objectives, assumptions or future events or performance are not historical
facts and are forward-looking statements. These statements are often, but not
always, made through the use of words or phrases such as believe, will,
expect, anticipate, estimate, intend, plan and would. For example, statements
regarding the plans and objectives of management are forward-looking
statements. Forward-looking statements are not guarantees of performance.
They involve known and unknown risks, uncertainties and assumptions that may
cause actual results, levels of activity, performance or achievements to
differ materially from those expressed or implied. Some of these risks
include, but are not limited to, the risk that we cannot retain key
executives. For additional information about risks and uncertainties we face
and a discussion of our financial statements and footnotes, see documents we
file with the SEC, including our most recent annual report on Form 10-K and
all subsequent periodic reports. We assume no obligation and expressly
disclaim any duty to update forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect the occurrence
of subsequent events.
Contact:
Michael Watts
Vice president, investor relations and
corporate communications
858-410-8673

SOURCE Gen-Probe Incorporated

Michael Watts, Vice president, investor relations and corporate communications
of Gen-Probe Incorporated, +1-858-410-8673